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Among the many interferon-induced proteins that carry out multiple cellular functions of interferons is the family of
enzymes called 29-59 oligoadenylate synthetases. We examined the anticellular and antiviral activities of a specific member
of that family, the P69 isozyme. P69 was expressed in human cells by transfection and shown to be localized primarily in the
endoplasmic reticulum. For further studies, permanent cell lines expressing different levels of P69 or an enzymatically
inactive mutant were isolated. Constitutive P69 expression caused inhibition of replication of encephalomyocarditis virus but
not of vesicular stomatitis virus, Sendai virus, or reovirus. Increasing levels of P69 expression also caused increasing
perturbations in cell growth properties. There was increasing accumulations of the P69-expressing cells in the G1 phase of
the cell cycle; cell-doubling time was increased by P69 expression; and there were many multinucleated cells in the
P69-expressing line, indicating a defect in cytokinesis. © 2000 Academic PressINTRODUCTION
Although interferon (IFN) inhibits the replication of
many viruses, the specific mechanisms of inhibition vary
among viruses of different families. The antiviral effects
of IFN are mediated by the various cellular proteins
whose synthesis is induced by IFN (Stark et al., 1998;
Vilcek and Sen, 1996). In addition to its antiviral effects,
IFN affects other cellular properties, most notably cell
growth. IFN treatment causes growth inhibition in many
cell lines and has cytotoxic effects on certain tumor cells.
These anticellular effects are also mediated by specific
IFN-inducible proteins. It has been difficult to assign
specific cellular functions to specific IFN-induced pro-
teins because more than 100 proteins are coordinately
induced by IFN treatment of cells. One approach that has
been partially successful so far is to express one IFN-
inducible protein at a time through the transfection of
appropriate expression vectors and challenge of the
cells with viruses. Such experiments have revealed vi-
rus-specific actions of the Mx proteins (Kochs and Haller,
1999; Staeheli and Haller, 1987; Staeheli et al., 1986), PKR
(Meurs et al., 1992), GBP (Anderson et al., 1999), and 225
(A) synthetase (Chebath et al., 1987b; Coccia et al., 1990;
Rysiecki et al., 1989). Recent gene knock-out studies
have complemented these transfection experiments
(Yang et al., 1995; Zhou et al., 1997).
The 225 (A) synthetase/RNase L system has been
studied extensively (Silverman, 1994). Synthesis of 225
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31(A) synthetase is induced by IFNs, but the protein is
inactive as such. It requires double-stranded (ds)RNA to
be activated so it can polymerize ATP to produce 29-59-
linked oligoadenylates. These products, 225 (A), in turn
activate RNase L by causing its dimerization. Activated
RNase L can then degrade viral and cellular RNA. Al-
though this general scheme is well established, it is not
clear why IFN induces many isozymes of 225 (A) syn-
thetase and what their specific functions are. The 225
(A) synthetases belong to three size classes: small, me-
dium, and large (Rebouillat and Hovanessian, 1999).
Within each size class, there are several members that
are produced by alternative splicing (Ichii et al., 1986;
Ghosh et al., 1991; Rutherford et al., 1991; Marie and
Hovanessian, 1992). Some of the isozymes undergo
posttranslational modifications, whereas others do not.
They are also located in different subcellular compart-
ments, suggesting different cellular functions (Chebath
et al., 1987a). The specific functions of only the small
class of 225 (A) synthetase have been studied so far.
The E16 cDNA encoding a 40-kDa isozyme was shown to
inhibit Mengo virus and encephalomyocarditis virus
(EMCV) replication (Chebath et al., 1987b; Rysiecki et al.,
1989). Similarly, the L3 cDNA encoding a 43-kDa isozyme
inhibits EMCV but not vesicular stomatitis virus (VSV)
(Coccia et al., 1990). A more recent study showed that
combined expression of RNase L and the 40-kDa 225
(A) synthetase isozyme caused inhibition of vaccinia vi-
rus replication (Diaz-Guerra et al., 1997). Members of the
medium-size class of human 225 (A) synthetases have
been cloned recently. Two such isozymes, P69 and P71,
are produced by alternative splicing (Marie and Hova-
nessian, 1992). The proteins are myristoylated, although
the modification is not required for its enzymatic activity.
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320 GHOSH, SARKAR, AND SENIn contrast, studies with recombinant P69 indicated that
its glycosylation may be required for enzymatic activity
(Sarkar et al., 1999a). The protein is active as a dimer and
completely dependent on dsRNA for its activation. The
P69 isozyme can synthesize 225 (A) oligomers contain-
ing up to 30 residues, whereas the small isozymes can
synthesize only smaller oligomers containing up to 6
residues (Sarkar and Sen, 1998). We recently identified
the catalytic domain of P69, and mutation of critical Asp
residues in the catalytic site inactivates the enzyme with-
out affecting its ability to bind dsRNA and ATP and to
dimerize (Sarkar et al., 1999b).
We report the cellular effects of P69. Cells expressing
P69 or its inactive mutant were isolated, and their anti-
viral and cell growth properties were studied. P69 was
shown to specifically inhibit EMCV replication and to
affect several cell growth properties.
RESULTS
Subcellular location of P69
For all experiments reported here, we used P69 ex-
pression vectors driven by a CMV early promoter. More-
over, the P69 protein had a Flag epitope tag at its car-
boxyl-terminus to facilitate specific and sensitive detec-
tion of the protein. When human HT1080 cells were
transfected with the P69 expression vector, a high level
of the protein was expressed. An anti-Flag antibody was
used to determine the subcellular location of P69 with
the use of immunofluorescence analysis. The protein
was distributed throughout the cell but excluded from the
nucleus. Its distribution, however, was not uniform: it was
present in punctuated bodies throughout the cytoplasm
and in the nuclear envelope (Fig. 1A). Because the P69-
associated subcellular structure appeared to be the en-
doplasmic reticulum (ER), we stained the cells for BIP, a
marker protein for the ER membrane, as well (Fig. 1B).
Superimposition of the two images (Fig. 1C) showed that
the majority of P69 was indeed associated with the ER,
as marked by the merging of the green and red colors to
produce a yellow staining pattern. Note that a portion of
the P69 pool, however, was not associated with the ER,
as demonstrated by the persisting green stain in some
parts of the cell (Fig. 1C).
Establishment of cell lines expressing P69
constitutively
To carry out investigation of the antiviral and the anti-
cellular properties of P69, we established cell lines ex-
pressing P69. P69 was expressed from the expression
vector PDR2-hyg, which also expressed a hygromycin
resistance gene. Three stable cell clones expressing
different levels of WtP69 and one clone containing empty
PDR2-hyg were used for further studies. As expected, the
PDR2-hyg clone did not express any P69 (Fig. 2A).Among the three WtP69 clones, clone 4 expressed the
lowest level of P69, whereas clone 9 expressed the
highest level and clone 10 expressed an intermediate
level of P69. We also expressed an enzymatically inactive
mutant of P69 (DADA P69) from the same vector and
isolated a cell clone (clone 6) that expressed the mutant
P69 to approximately the same level as clone 9 (Fig. 2A).
The functional activity of P69 expressed in different cell
lines was tested by carrying out 225 (A) synthetase
assays with their extracts (Fig. 2B). Proportional to the
cellular P69 protein levels, clone 9 had the highest ac-
tivity, clone 10 had an intermediate level, and clone 4 had
a low level. Extracts from the vector-transfected cells and
clone 6, in contrast, did not have any enzymatic activity.
To compare the level of P69 expression in clone 9, we
treated HT1080 cells with various doses of IFN and
measured P69 expression by Western blotting with a P69
antiserum. The level of P69 expression in clone 9 was
comparable to that in cells treated with 100 U/ml IFN (Fig.
2C). These characterized cell clones were used for func-
tional studies as described later.
Antiviral properties of P69-expressing cells
Effects of P69 on the replication of four viruses, VSV,
EMCV, Sendai virus, and reovirus, were examined using
cytopathic effect (CPE) assays (Fig. 3). Clone 9, express-
ing WtP69 (wells A1, B1, C1 and A4, B4, C4); clone 6,
expressing mutant P69 (wells A2, B2, C2 and A5, B5, C5),
and PDR2-hyg, the empty vector, containing clone (wells
A3, B3, C3 and A6, B6, C6), were used for this experi-
ment. Uninfected cells did not show any CPE as judged
by their staining (C1–C3), but VSV infection caused CPE
in all three cell lines (A1–A3). When the cells were pre-
treated with IFN, however, they were protected against
the CPE caused by VSV infection (B1–B3). Similarly, in-
fection with Sendai virus (B4–B6) or reovirus (C4–C6)
caused complete CPE in all three cell lines. In contrast,
infection with EMCV had a differential effect in the three
cell lines. Although in clone 6 (A5) and PDR2-hyg (A6)
EMCV caused complete cell death, clone 9 was mostly
protected (A4) from the CPE. Thus it appeared that
WtP69, but not the mutant protein, protected cells
against EMCV but not the other three viruses.
To more quantitatively test this conclusion, virus yield
reduction assays were performed with VSV and EMCV
(Table 1). Replication of neither virus was inhibited in the
vector. As expected, increasing doses of IFN (7–9) in-
creasingly inhibited the replication of both viruses. As
anticipated from Fig. 3, in Wt P69-expressing cells, rep-
lication of EMCV, but not of VSV, was inhibited (3–5).
Moreover, the degree of inhibition of EMCV was propor-
tional to the level of expression of P69 in the three cell
clones. In clone 9, the degree of EMCV inhibition was
comparable to that in cells treated with 10 U/ml IFN
wn in r
321CELLULAR EFFECTS OF P69(compare 3 and 7). These results clearly demonstrated a
virus-specific antiviral effect of P69.
Cell growth regulatory effects of P69 expression
We tested whether constitutive expression of P69 af-
fects cell growth properties in a series of experiments.
FIG. 1. Colocalization of P69 with the ER marker BiP. HT1080 cells
microscopy for the expression of P69 and BiP. (A) The expression patte
pattern of BiP detected by a specific monoclonal antibody and sho
superimposition of the previous images.Cells expressing P69 grew more slowly, and the more
P69 was expressed, the slower was the cell growth (Fig.4). Clone 9 was the most severely affected, whereas the
growth rate of DADA P69 6 was comparable to that of the
untransfected cells, indicating that the observed effect
on cell growth was due to the enzymatic activity of P69.
The doubling times of the different cell lines were as
follows: HT1080, 14.9 h; clone 4, 16.6 h; DADA clone 6,
transfected with a P69 expression vector and analyzed by confocal
69 detected by Flag antibody and shown in green. (B) The expression
ed. (C) Colocalization of the two proteins, as shown in orange, bywere
rn of P15.2 h; clone 10, 20.9 h; and clone 9, 30.5 h.
The overall inhibition of cell growth observed in Fig. 4
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322 GHOSH, SARKAR, AND SENcould be the result of a selective arrest of the P69-
expressing cells in a specific stage of the cell cycle. This
possibility was examined in Fig. 5 by performing a cell
cycle analysis of three clones. All cells were harvested
during growth phase, stained with propidium iodide, and
FACS scanned for their DNA content. Under the experi-
mental conditions used, in the vector-transfected PDR2-
hyg cells, 45% of the cells were in the G1 phase, 39%
FIG. 2. Levels of expression of P69 in permanently transfected lines.
Several clones of HT1080 cells transfected with WtP69, DADA P69, or
the empty expression vector PDR2 were tested. (A) Western blot anal-
ysis of cell extracts with a polyclonal Flag antibody. (B) 225 (A) Syn-
thetase activities of cell extracts. (C) Lanes 1–5, HT1080 cells were
treated with the indicated doses of IFN. Lane 6, clone 9. Cellular protein
(20 mg) was analyzed by Western blotting with mouse polyclonal P69
anti-serum (Marie et al., 1999). The bar graph shows the quantification
of P69 levels in different cells.were in the S phase, and 16% were in G2/M phase. In
clone 9, the relative proportions of the cells were altered:
15% more cells were in the G1 phase, 10% fewer were in
he S phase, and 5% less were in the G2/M phase. In
clone 10, the cell cycle distribution was also altered but
not as strongly as in clone 9. These results suggest that
P69 expression affects the rate of normal progression
through the cell cycle, although the cells are not com-
pletely blocked at any stage of the cell cycle.
Another effect of P69 expression on cell growth prop-
erties was apparent when clone 9 was examined by
fluorescence microscopy after DNA staining with DAPI.
Four fields of such staining are shown in Fig. 6. There
were many cells containing multiple nuclei, as indicated
by the arrows. They were also apparent in light micros-
copy (Fig. 6, left panels). It appears that these cells have
undergone unregulated mitosis and nuclear divisions,
but cytokinesis and cell division have not followed. Sim-
ilar multinucleated cells were observed in clone 10 but
not in clone 6 expressing mutant P69 (not shown).
DISCUSSION
FIG. 3. CPEs of different viruses in cell lines expressing P69. Three
cell lines, WtP69 clone 9, DADA P69 clone 6, and PDR2-hyg, were
infected with VSV, EMCV, Sendai virus, or reovirus, and viral CPEs were
monitored by cell staining. A1: P69 clone 9, VSV; A2: DADA P69 clone
6, VSV; A3: clone PDR2-hyg, VSV; B1: P69 #9, VSV, pretreated with 500
U/ml IFN-b; B2: DADA P69 #6, VSV, pretreated with 500 U/ml IFN-b; B3:
PDR2-hyg, VSV, pretreated with 500 U/ml IFN-b; C1: P69 #9, uninfected;
2: DADA P69 #6, uninfected; C3: PDR2-hyg, uninfected; A4: P69 #9,
MCV; A5: DADA P69 #6, EMCV; A6: PDR2-hyg, EMCV; B4: P69 #9,
endai virus; B5: DADA P69 #6, Sendai virus; B6: PDR2-hyg, Sendai
irus; C4: P69 #9, reovirus; C5: DADA P69 #6, reovirus; C6: PDR2-hyg,
eovirus.We have studied the structure-function relationships of
different isozymes of 225 (A) synthetases. These studies
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323CELLULAR EFFECTS OF P69are complemented by investigation of specific cellular
functions of the different isozymes. The central incentive
for these studies is the desire to understand why so
many isozymes of 225 (A) synthetase exist. Are these
proteins induced differently; are they activated by differ-
ent agents; and do they produce different products, re-
side in different subcellular compartments, and have
different cellular activities? At the biochemical level, the
small isozyme 9-2 functions as a tetramer, whereas the
medium isozyme P69 functions as a dimer (Sarkar et al.,
1999a; Ghosh et al., 1997). The two subunits of the P69
eem to contain two active centers, because a het-
rodimer containing one wild-type subunit and another
nactive subunit has half the specific activity of the Wt
omodimer (Sarkar et al., 1999b). Both 9-2 and P69 con-
T
Reduction of EMCV and VSV Yields in HT10
Serial no. Cell type
IFN dosea
(U/ml) Viru
1. HT1080 1.6
2. PDR2-hyg 2
3. WtP69 #9 1.2
4. WtP69 #10 1.6
5. WtP69 #4 3.2
6. DADA P69 #6b 1.2
7. HT1080 10 1.5
8. HT1080 100 1.3
9. HT1080 1000 2.4
Note. Cells (5 3 105) from each line were infected with 1 m.o.i. of e
a IFN-b was used for 18 h on HT1080 cells.
b DADA P69 is an enzymatically inactive mutant (Sarkar et al., 1999b
FIG. 4. Growth rates of P69-expressing cell lines. Equal numbers of
cells from each line were seeded onto 24-well plates. Cells were
trypsinized and counted from three wells for each line every day afterp
t
plating. The error bars show the spread of cell counts among the three
samples.ain similar catalytic domains in which three Asp resi-
ues form the catalytic triad. Despite these similarities,
owever, the two isozymes produce very different pro-
iles of 225 (A) products (Sarkar and Sen, 1998). Much
onger 225 (A) products are synthesized by P69 com-
ared with 9-2 and other small synthetases. There are
ndications that the length of 225 (A) may affect its
unctions. Although a trimer can activate RNase L, a
odecamer cannot. Moreover, the longer 225 (A) mole-
ules can bind to RNase L as strongly as the shorter
olecules, thus serving as inhibitors of RNase L activa-
ion (P. Torrence, personal communication). It is likely,
herefore, that the RNase L activation potential of 225 (A)
roducts made by different isozymes will depend on the
elative abundance of the shorter and the longer 225 (A)
olecules. Hence, products made by P69, which is
icher in longer 225 (A) species, may have different
ellular effects than the products made by the smaller
sozymes. The two enzymes may also be able to use
ifferent acceptors, such as NAD or GTP, differently. The
ellular functions of these putative alternative products,
owever, remain unknown.
To study cellular functions of P69 in the absence of
ther 225 (A) synthetase isozymes, we needed to estab-
ish cell lines expressing P69. As reported here, we were
ble to achieve that without problems. The same was not
rue for the small isozyme 9-2, whose sustained expres-
ion caused cell death (our unpublished observation).
hat observation already suggested that the different
sozymes have different cellular functions. A potential
eason for their different effects could be their locations
n the cell (Chebath et al., 1987a). Our results clearly
how (Fig. 1) that P69 is associated with ER. That it is not
n the nucleus or on the plasma membrane has been
l Clones of P69, DADA P69, and PDR2-hyg
EMCV VSV
Log inhibition Virus yield Log inhibition
1.1 3 107
1 3 107 0.04
2.2 8 3 106 0.14
1.0 1 3 107 0.04
0.7 3.2 3 107
0.13 1 3 107 0.04
2.03 4 3 104 2.44
3.14 1 3 104 3.04
3.90 3 3 103 3.64
MCV or VSV.ABLE 1
80 Cel
s yield
3 107
3 107
3 105
3 106
3 106
3 107
3 105
3 104
3 103
ither Ereviously reported (Marie et al., 1990). The same au-
hors noted the location of P69 to be cytoplasmic and in
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324 GHOSH, SARKAR, AND SENthe nuclear membrane. Our results are consistent with
those observations except that we have been able to
further localize it to the ER in the cytoplasm. The subcel-
lular location of P69 in the ER may suggest why unlike
other isozymes, it contains sugar modification (Sarkar et
al., 1999a): the initial stages of protein glycosylation take
place in the ER. It is curious to note the recent descrip-
tion of the stress response proteins Irea and Ireb (Tira-
ophon et al., 1998; Wang et al., 1998), which are located
FIG. 5. Cell cycle distribution of cells expressing P69. Cells were
analyzed for DNA contents by flow cytometry. The proportion of cells in
the G1, S, and G2/M phases are shown by the numbers on the top of
ach peaks.n the ER and contain ribonuclease domains homolo-
ous to RNase L. Can these proteins be activated by the
M
oong 225 (A) products of P69, or can their activation by
nfolded protein response be inhibited by 225 (A)? Fu-
ure studies may reveal such interesting links.
P69 expression caused inhibition of EMCV replication.
fter the experiments reported here were completed,
arie et al. (1999) reported similar results in a mouse
ell line. Our results showed that the anti-EMCV activity
as P69 dose dependent and enzyme activity depen-
ent, thus demonstrating that the dsRNA-binding prop-
rty of P69 or its overexpression, clogging up the ER, was
ot responsible for the anti-EMCV effect. Moreover, the
ffect was virus specific: three other viruses were not
nhibited by P69 expression. The reason for this selec-
ivity remains unclear. It is known that during EMCV
eplication, the viral dsRNA can bind to the small 225 (A)
ynthetase (Gribaudo et al., 1991); the same may be true
or P69, and the other viruses may not be able to produce
uch accessible dsRNA and thereby activate the en-
yme. It is also possible that even if 225 (A) is produced
n cells infected with other viruses, it may not affect viral
etabolism. The 225 (A) action is most likely mediated
y RNase L activation, although other actions of 225 (A)
hould not be ruled out especially in view of the recent
eport that IFN can inhibit EMCV replication substantially
ven in cells lacking functional genes of PKR, RNase L,
nd Mx (Zhou et al., 1999).
The anticellular effects of P69 described here are
ovel and interesting. Clearly, expression of increasing
uantities of P69 caused increasing inhibition of cell
rowth. This could be the reason why higher expressors
f P69 were not isolated during cloning after cell trans-
ection. Again, the inactive enzyme did not cause cell
rowth inhibition, indicating that 225 (A) production is
eeded. But what activates P69 in the absence of viral
nfection? If 225 (A) is constitutively produced, how does
t affect cell growth? Is RNase L required for this pro-
ess? Some of these questions can be approached by
etting up tetracycline- or ecdysone-inducible P69 ex-
ression systems or by using RNase L2/2 cells. The
ncreased doubling time of the P69-expressing cells may
e connected to the observed distortion in the cell cycle
nd the formation of multinucleated cells. The multinu-
leated cells, being unable to produce daughter cells,
ay drop out from the population, thus slowing down the
opulation-doubling time. It will be illuminating to deter-
ine the cause of the multinucleated phenotype. A loss
f regulation of the mitotic check point is often the cause
f such abnormality. For example, the human T cell
eukemia virus oncoprotein Tax binds to the human mi-
otic checkpoint protein MAD1 (Jin et al., 1998) and
locks its function, causing the formation of multinucle-
ted cells. Whether P69 similarly alters the function of
AD1 or other mitotic checkpoint proteins remains an
pen question.
325CELLULAR EFFECTS OF P69FIG. 6. Presence of multinucleated cells in clone 9. Cells were stained with DAPI. Images of four fields are shown. Dark fields are on the left, and
fluorescent fields are on the right. The arrowheads point multinucleated cells.
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326 GHOSH, SARKAR, AND SENMATERIALS AND METHODS
Isolation of P69-expressing cell lines
For stable expression, carboxyl-terminally Flag-tagged
wild-type P69 and its mutant were subcloned in PDR2-
hyg vector. The human fibrosarcoma cell line HT1080
was transfected with Lipofectamine reagent (Life Tech-
nologies, Grand Island, NY), with the vector containing
WtP69 or DADA P69 mutant insert or an empty vector
(PDR2-hyg) as control. Cells were selected in the pres-
ence of hygromycin (Calbiochem, San Diego, CA) at a
concentration of 400 mg/ml. Drug-resistant clones were
obtained after 21 days. Thirty clones from each construct
(P69, P69 DADA) were tested for protein expression by
Western blotting and by immunofluorescence. Represen-
tative clones for different levels (low, medium, and high)
were selected. Clonal lines containing PDR2 vector with
WtP69, with DADA P69 mutant insert, or without insert
are referred to as WtP69, DADA P69, and PDR2-hyg,
respectively.
Western blotting
Cell extract containing 50 mg protein was analyzed by
SDS–PAGE and Western blotted with Flag polyclonal
antibody (Santa Cruz Biochemicals, Santa Cruz, CA).
225 (A) Synthetase assay
Next 100 mg protein from each cell extract was bound
o Flag beads in lysis buffer (300 mM NaCl, 20 mM
ris z Cl, pH 7.4, 10% glycerol, 10 mM imidazole, 5 mM
b-mercaptoethanol, 0.3% Triton X-100, 1 mM PMSF, 2
mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pep-
statin) for 2 h at 4°C. At the end of binding, the beads
were washed twice with washing buffer (lysis buffer with
450 mM NaCl). The activity assay was performed with
the protein bound to the Flag beads in a 25-ml reaction
volume (Sarkar et al., 1999a). The reaction products were
analyzed by thin-layer chromatography.
Cells
HT1080 (human fibrosarcoma cells) and HeLa cells
were grown in DMEM with 10% FBS and antibiotics.
Viruses
EMCV (ATCC VR-1314) was obtained from the labora-
tory of Dr. Robert Silverman (Cleveland Clinic Founda-
tion) and was expanded. VSV, New Jersey strain, was
obtained from the laboratory of Dr. Amiya Banerjee. Reo-
virus (ATCC VR-824) and Sendai virus (ATCC VR-907)
were obtained from American Type Culture Collection
(Rockville, MD).
Virus infectionCells were seeded onto individual wells of a 6-well
dish (5 3 106 cells/well). Infection with EMCV and VSV
t
cas done with 1 multiplicity of infection (m.o.i.) and kept
or absorption for 1 h at 37°C in a medium containing no
erum. After the absorption period, the virus was re-
laced with fresh DMEM with 2% serum and kept at
7°C for 8 h for single cycle experiment (Coccia et al.,
990). After 8 h, the whole plate was frozen at 280°C and
nderwent a freeze/thaw cycle three times to release the
ell-associated virus. Both the supernatant and cell de-
ris were collected and pelleted down. The supernatant
or each sample was transferred as virus stock and
tored at 280°C freezer. Virus stocks from IFN-treated
ells were made by treating the HT1080 cells with IFN-b
at concentrations of 10, 100, and 1000 U/ml for 18 h
followed by EMCV or VSV infection in the same way as
mentioned earlier.
Virus yield reduction assay
The progeny virus produced from various lines at var-
ious experimental conditions as mentioned earlier were
diluted into 10-fold serial dilutions and titered by plaque
assay on HT1080 cells (for EMCV) and HeLa cells (for
VSV).
CPE assay
For CPE detection, monolayers of cells containing
WtP69 (clone 9), DADA P69 (clone 6), and PDR2-hyg lines
were seeded in individual well of 24-well plates at a
concentration of 1 3 105 cells/well. Infection was done
ith 0.1 PFU/cell of virus in case of EMCV and VSV, 16
CID50/cell for Sendai virus, and 50 TCID50/cell for reovi-
rus; these were kept for absorption for 1 h at serum-free
medium at 37°C. After the infection, the unadsorbed
virus was removed, and fresh medium containing 2%
serum was added to the monolayers and incubated at
37°C. The infection was stopped when the monolayers
of the vector cell line were destroyed by different virus
infections and was compared with that of P69 and DADA
mutant-expressing lines. As positive control, the same
cell lines were treated with 500 U/ml IFN-b for 18 h
efore virus infection (VSV). At the end of infection pe-
iod, the cell monolayers were washed with PBS twice to
emove all the dead cells and cell debris, followed by
taining with 0.02% crystal violet in 50% methanol for 10
in at room temperature. After staining, the monolayers
ere washed again with water to remove the excess
tain, air dried, and visualized.
ell growth assay
Cells (3 3 104) were seeded onto each well of 24-well
ish. For each time point, the cells were trypsinized and
he live cells were counted in triplicate. The growth curve
as drawn by plotting cell number versus time. Doublingime for each line was calculated by fitting the growth
urve with exponential growth equation.
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327CELLULAR EFFECTS OF P69Cell cycle analysis
For cell cycle analysis, cells from different lines were
plated at 1.4 3 106/100-mm dish concentration and al-
lowed to grow at 37°C. On the fourth day, cells were
trypsinized, washed in PBS twice, and permeabilized in
70% ethanol for 30 min at 4°C. The cell pellet was then
washed twice in PBS, followed by treatment with 5 ml of
Nase (0.2 U/ml) in 1 ml of cell suspension and incu-
bated for 30 min at 37°C. The cell suspension was
chilled on ice, and 100 ml of propidium iodide (0.5 mg/ml)
as added to each tube. Red fluorescence was moni-
ored in a flow cytometer (Becton Dickinson), and the
ata were acquired using Mod Fit LT software. Cell cycle
rofiles were drawn using Cell Quest program.
mmunofluorescence
P69-expressing cells were fixed in acetone/methanol
1:1) solution for 1 min, followed by blocking in 3% BSA
nd 5% goat serum in PBS for 40 min at room tempera-
ure. For detection of Flag-tagged P69, the fixed cells
ere incubated with polyclonal anti-Flag antibody (1000-
old diluted) for 2 h at room temperature. At the end of the
ncubation period, the coverslips were washed with
BS–Tween 20 buffer three times, followed by incubation
ith FITC-tagged goat anti-rabbit antibody (Life Technol-
gies) in 1:2000 dilution. For ER localization, monoclonal
ntibody against ER marker Grp 78 (BiP) was used and
etected with a goat anti-mouse antibody tagged with
exas Red and visualized under confocal microscope.
or visualization of cell nuclei, cells were fixed as de-
cribed above and washed with PBS. Coverslips were
ounted on slides with Vectashield-DAPI (Vector Labo-
atories, Burlingame, CA) and viewed under fluorescent
icroscope.
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